anky1212
☆    

India,
2019-02-21 05:05

Posting: # 19951
Views: 280
 

 Health Canada Study reports [Regulatives / Guidelines]

Dear All,

As per Health canada guidance document, "To avoid study bias, comparative bioavailability studies should be conducted in such a way that the subjects are not aware of which product (test or reference) is being administered. Furthermore, the persons checking for adverse reactions and those conducting the bioanalysis of samples should not know the treatment sequence."

In this case, if adverse events is ongoing, analysis both analytical and statistical phase completed, shall we submit treatment or code in study report?

Upto which phase guidance is applicable?

After completion of statistical phase if adverse event is still ongoing, still we need to follow guidance?

Thanks
Ankur Patel
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,490 posts in 4,135 threads, 1,335 registered users;
online 8 (0 registered, 8 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 13:34 CEST

Not to be absolutely certain is, I think,
one of the essential things in rationality.    Bertrand Russell

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5